Table of Contents Author Guidelines Submit a Manuscript
Canadian Journal of Gastroenterology and Hepatology
Volume 2016 (2016), Article ID 6260271, 7 pages
http://dx.doi.org/10.1155/2016/6260271
Research Article

Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action

1Department of Biology, University of Toronto Mississauga, 3359 Mississauga Road, Mississauga, ON, Canada L5L 1C6
2Toronto Centre for Liver Disease, Toronto General Hospital, 200 Elizabeth Street 9EN, Toronto, ON, Canada M5G 2C4

Received 5 November 2015; Accepted 10 November 2015

Copyright © 2016 Nicole A. Tillie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to Cite this Article

Nicole A. Tillie, Jayson L. Parker, and Jordan J. Feld, “Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action,” Canadian Journal of Gastroenterology and Hepatology, vol. 2016, Article ID 6260271, 7 pages, 2016. doi:10.1155/2016/6260271